Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure

Abstract

Vascular tolerance develops rapidly in isolated vascular strips exposed to millimolar concentrations of nitroglycerin. Several mechanisms, including depletion of sulfhydryl groups, reduced biotransformation of nitrates to NO or nitrosothiols, oxygen free radical injury, and downregulation of a membrane-bound enzyme or a nitrate receptor, have been proposed, but the exact mechanism responsible for in-vitro tolerance remains unknown. In-vivo tolerance of the beneficial effects of nitrates on hemodynamics, myocardial ischemia, and exercise performance develops rapidly. It has been suggested, but remains to be proven, that development of venous tolerance and not arterial tolerance is responsible for the attenuation of nitrate effects during long-term nitrate therapy. Several mechanisms, including neurohormonal activation, depletion of sulfhdryl groups, and the shift of fluid from the extravascular to intravascular compartment have been implicated. However, the use of agents to counteract these mechanisms (ACE inhibitors, sulfhydryl donors, diuretics) has produced conflicting results. Thus, at present the mechanism responsible for in vivo tolerance to nitrates remains unknown. Both in vitro and in vivo vascular tolerance to nitrates can be prevented or minimized by providing nitrate-free or low-nitrate intervals. However, during nitrate-free periods, rebound phenomena (rest angina in patients with ischemic heart disease or a deterioration in exercise performance prior to the renewal of the morning dose in patients with stable angina) remain a clinical concern. When treating patients with stable angina pectoris, it must be recognized that none of the nitrate preparations or formulations can provide round-the-clock antianginal or antiischemic prophylaxis. In these patients, beneficial antianginal and antiischemic effects of nitrates for 10-14 hours during the daytime can be maintained by using formulations and dosing regimens that avoid or minimize the development of tolerance (standard formulation of isosorbide-5-mononitrate, 20 mg in the morning and 7 hours later; slow-release formulation of isosorbide-5-mononitrate, 120-240 mg once a day; or nitroglycerin patch delivering 0.6 nitroglycerin per hour for 10-12 hours each day). Only the patch on and off treatment is associated with nitrate rebound. Although intermittent nitrate therapy is not associated with the development of tolerance, this strategy cannot be recommended for treating unstable angina because rebound angina during nitrate-free periods complicates clinical decision making. In the acute phase of unstable angina, continuous treatment with intravenous nitroglycerin is recommended because it permits rapid up- or down-titration. Tolerance towards antianginal and antiischemic effects does develop in a substantial number of patients with 24 hours, but this can be overridden by dose escalation and restoration of the therapeutic effectiveness of nitroglycerin. Tolerance towards the beneficial effects of nitrates on hemodynamics and on exercise performance also de...

RETRACTED ARTICLE: Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study

“…At the time, we hypothesised that the greater effects among intermittent compared to daily users may be due to tachyphylaxis associated with daily nitrate use. Tachyphylaxis is commonly observed when treating patients with coronary heart disease with nitrates [20] and similar effects have been observed in ovariectomised rats in which the beneficial effects of nitrates on bone mass decrease with increasing frequency of application [21].…”

Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics

“…41 -44 In addition, an increase in angina at rest has been observed during nitrate-free periods with transdermal nitrate formulations, as has a decrease in exercise duration prior to retreatment (often referred to as time-zero effect). 41,42 However, neither an increase in nocturnal angina nor the time-zero effect have been observed with orally administered long-acting nitrates. 40 The exact mechanism underlying the development of tolerance is not fully understood.…”

Effect of Isosorbide-5-Mononitrate on Exercise Performance and Clinical Status in Patients with Congestive Heart Failure

“…On a chronic basis, isosorbide dinitrate-hydralazine improved survival in patients with Class 2–3 heart failure [1]. Although the development of tolerance could limit the long-term efficacy of the drug when used on a chronic basis [38], tolerance may be minimized by an appropriate dosing regimen such as the once-daily sustained release formulation used in this study, or with appropriate concomitant therapy such as hydralazine [39, 40]or angiotensin-converting enzyme inhibitor [36, 41]. The present study showed that isosorbide mononitrate in addition to captopril was well tolerated and improved treadmill exercise time in certain patients with heart failure.…”